Garrelts J C, Godley P J, Peterie J D, Gerlach E H, Yakshe C C
Department of Pharmacy, St. Francis Regional Medical Center, Wichita, Kansas.
Antimicrob Agents Chemother. 1990 May;34(5):931-3. doi: 10.1128/AAC.34.5.931.
The effect of sucralfate on the bioavailability of ciprofloxacin was evaluated in eight healthy subjects utilizing a randomized, crossover design. The area under the concentration-time curve from 0 to 12 h was reduced from 8.8 to 1.1 micrograms.h/ml by sucralfate (P less than 0.005). Similarly, the maximum concentration of ciprofloxacin in serum was reduced from 2.0 to 0.2 micrograms/ml (P less than 0.005). We conclude that concurrent ingestion of sucralfate significantly reduces the concentrations in serum produced by a 500-mg dose of ciprofloxacin. On the basis of these findings, ciprofloxacin and sucralfate should not be administered concurrently.
采用随机交叉设计,在8名健康受试者中评估了硫糖铝对环丙沙星生物利用度的影响。硫糖铝使0至12小时浓度-时间曲线下面积从8.8微克·小时/毫升降至1.1微克·小时/毫升(P<0.005)。同样,血清中环丙沙星的最大浓度从2.0微克/毫升降至0.2微克/毫升(P<0.005)。我们得出结论,同时服用硫糖铝会显著降低500毫克剂量环丙沙星产生的血清浓度。基于这些发现,环丙沙星和硫糖铝不应同时给药。